

Abstract

This case report sheds light on cardiac prosthesis-related hemolytic anemia (CPHA), a potentially life-threatening complication frequently associated with mechanical heart valve prostheses. While historically prevalent, advancements in valve design and surgical techniques have markedly reduced the occurrence of clinically significant hemolysis. Nevertheless, subclinical hemolysis remains a concern, particularly with modern prosthetic valves. Management of CPHA depends on symptom severity, with mild cases benefiting from various therapies, including pentoxifylline (PTX), as suggested by recent research. These insights reflect the evolving landscape of CPHA management, emphasizing tailored approaches based on individual patient profiles.